Logo

PRGO

Perrigo Company plc

PRGO

Perrigo Company plc • NYSE
$13.35 ▲ 1.68% (+0.22)
Market Cap $1.84 B
52w High $30.93
52w Low $12.17
Dividend Yield 1.16%
P/E -63.57
Volume 2.29M
Outstanding Shares 137.61M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $1.043B ▼ $304.5M ▼ $7.5M ▲ 0.719% ▲ $0.05 ▲ $161.8M ▲
Q2-2025 $1.056B ▲ $317.5M ▼ $-8.4M ▼ -0.795% ▼ $-0.061 ▼ $129.1M ▲
Q1-2025 $1.044B ▼ $345.4M ▲ $-6.4M ▲ -0.613% ▲ $-0.05 ▲ $127.2M ▼
Q4-2024 $1.138B ▲ $271.7M ▼ $-44.5M ▼ -3.909% ▼ $-0.32 ▼ $193.4M ▲
Q3-2024 $1.087B $324M $-21M -1.931% $-0.15 $161.7M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $432.1M ▼ $10.084B ▼ $5.638B ▲ $4.447B ▼
Q2-2025 $454.2M ▲ $10.094B ▲ $5.622B ▲ $4.472B ▲
Q1-2025 $409.9M ▼ $9.76B ▲ $5.396B ▲ $4.364B ▲
Q4-2024 $558.8M ▼ $9.648B ▼ $5.328B ▼ $4.319B ▼
Q3-2024 $1.462B $11.203B $6.637B $4.566B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $12.7M ▲ $51.7M ▼ $-21.4M ▼ $-50.3M ▲ $-22.1M ▼ $29.8M ▼
Q2-2025 $-500K ▼ $75.9M ▲ $-3.8M ▲ $-54M ▲ $44.3M ▲ $56.7M ▲
Q1-2025 $100K ▲ $-64.5M ▼ $-25.7M ▲ $-61.8M ▲ $-148.9M ▲ $-90M ▼
Q4-2024 $-44.5M ▼ $312.6M ▲ $-37.1M ▼ $-1.154B ▼ $-904.7M ▼ $274.9M ▲
Q3-2024 $-20.9M $42.2M $212.7M $653.3M $920.7M $15.1M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
Consumer SelfCare Americas
Consumer SelfCare Americas
 $740.00M ▲$620.00M ▼$620.00M ▲$650.00M ▲
Consumer SelfCare International
Consumer SelfCare International
 $390.00M ▲$420.00M ▲$430.00M ▲$400.00M ▼

Five-Year Company Overview

Income Statement

Income Statement Perrigo’s sales have been fairly steady over the past several years, but profits have been under pressure. Gross profit has held up reasonably well, yet operating income has shrunk compared with earlier years, leaving only a thin profit cushion from core operations. After interest, taxes, and various one‑off items, the company has reported small but persistent net losses each year. This suggests the underlying business can generate value-added products and services, but overheads, financing costs, and restructuring or transformation expenses are weighing down the bottom line. The main risk here is that, until profitability improves, the company has limited room for error if growth slows or costs rise unexpectedly.

Balance Sheet

Balance Sheet The balance sheet shows a sizeable asset base and a solid level of shareholder equity, which means the company still has a meaningful buffer supporting its operations. Debt is significant but not extreme, and it has started to edge down in recent years, a positive trend for financial stability. Cash on hand is adequate but not abundant, especially compared with the overall size of the business and its debt load. Equity has drifted lower over time, reflecting ongoing losses and possibly past write‑downs. Overall, the balance sheet looks acceptable but not overly conservative; it can support the current strategy, but it reinforces the importance of restoring consistent profitability and continued debt discipline.

Cash Flow

Cash Flow Despite accounting losses, Perrigo has consistently generated positive cash from its day‑to‑day operations. Free cash flow has generally been positive and has improved compared with the weakest year in the period, helped by disciplined, relatively modest capital spending. This means the business model does convert sales into cash, even if reported earnings are under strain. That said, the level of free cash flow is not exceptionally high relative to the size of the company and its debt, so management’s ongoing focus on efficiency, working capital, and capital allocation will be important. The positive trend in cash generation is a key strength, but it still needs to be scaled up to comfortably cover all strategic and financial commitments.

Competitive Edge

Competitive Edge Perrigo holds a leading position in over‑the‑counter private‑label (store brand) healthcare products, especially in the U.S., which gives it strong scale advantages, a wide product range, and deep relationships with major retailers. These factors create meaningful barriers for smaller rivals trying to break in. However, the same powerful retailers that rely on Perrigo also hold considerable bargaining power, which can cap pricing and margins. In Europe, Perrigo complements its private‑label strength with branded products, giving it a hybrid model that can tap both value and premium segments. The company’s strategic pivot to being a focused “self-care” consumer health player aims to sharpen this positioning, but success will depend on executing well against both global consumer health giants and other cost‑efficient generic and private‑label manufacturers.

Innovation and R&D

Innovation and R&D Perrigo’s innovation engine is geared more toward consumer health products and operational excellence than high‑risk, high‑reward pharmaceutical breakthroughs. The standout example is Opill, the first daily oral contraceptive approved for over‑the‑counter use in the U.S., which gives the company a clear first‑mover advantage in an important women’s health category. Alongside product development, large efficiency programs like Project Energize and the supply chain reinvention effort aim to modernize manufacturing, improve service levels, and lower unit costs. Future growth is expected to lean on new offerings in women’s health and skincare, where branding and differentiation matter more. The main opportunity is to convert these initiatives into higher-margin, defensible product lines; the main risk is that innovation and cost savings may not fully offset ongoing price pressure and retailer bargaining power.

Summary

Perrigo is in the middle of a strategic transformation toward being a focused consumer self-care company. The core business shows steady revenues and reliable cash generation, but profitability at the bottom line has been weak and consistently negative. The balance sheet is reasonably solid, with meaningful equity and manageable—though not trivial—debt, and cash flows are improving, which supports the turnaround agenda. Competitively, the company benefits from scale, breadth, and long-standing retailer relationships in private-label OTC products, enhanced by a branded presence in Europe. Innovation efforts, highlighted by the pioneering Opill launch and major efficiency programs, offer paths to better growth and margins. The key questions going forward are whether Perrigo can translate its strategic pivot, cost initiatives, and new product pipeline into sustainably higher profits while carefully managing leverage and preserving its privileged place on retailers’ shelves.

NEWS

November 29, 2025 · 10:43 PM UTC

ROSEN, LEADING INVESTOR COUNSEL, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - PRGO

Read more

November 28, 2025 · 11:46 AM UTC

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Skye Bioscience and Perrigo and Encourages Investors to Contact the Firm

Read more

November 28, 2025 · 11:00 AM UTC

PRGO Investors Have Opportunity to Lead Perrigo Company plc Securities Fraud Lawsuit with the Schall Law Firm

Read more

November 28, 2025 · 9:00 AM UTC

Perrigo Company Shareholders with Large Losses Should Contact Robbins LLP for Information About the PRGO Class Action

Read more

November 27, 2025 · 4:35 PM UTC

ROSEN, SKILLED INVESTOR RIGHTS COUNSEL, Encourages Perrigo Company plc Investors to Secure Counsel Before Important Deadline in Securities Class Action - PRGO

Read more